MX2017013859A - Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. - Google Patents
Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña.Info
- Publication number
- MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapies
- limited
- integrin
- small molecule
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154554P | 2015-04-29 | 2015-04-29 | |
| US15/140,711 US10342866B2 (en) | 2015-04-29 | 2016-04-28 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| PCT/US2016/029683 WO2016176400A2 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013859A true MX2017013859A (es) | 2018-07-06 |
Family
ID=57198770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013859A MX2017013859A (es) | 2015-04-29 | 2016-04-28 | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
| MX2024002456A MX2024002456A (es) | 2015-04-29 | 2017-10-27 | Composiciones novedosas y métodos para inmunoterapias que comprenden adyuvantes del agonista del ligando receptor de integrina de molécula pequeña. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002456A MX2024002456A (es) | 2015-04-29 | 2017-10-27 | Composiciones novedosas y métodos para inmunoterapias que comprenden adyuvantes del agonista del ligando receptor de integrina de molécula pequeña. |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10342866B2 (enExample) |
| JP (2) | JP2018514562A (enExample) |
| KR (3) | KR20240052078A (enExample) |
| CN (1) | CN107820429B (enExample) |
| AU (1) | AU2016254034B2 (enExample) |
| CA (1) | CA2984316A1 (enExample) |
| IL (1) | IL255297B (enExample) |
| MX (2) | MX2017013859A (enExample) |
| SG (2) | SG11201708846XA (enExample) |
| WO (1) | WO2016176400A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240052078A (ko) * | 2015-04-29 | 2024-04-22 | 7 힐즈 인터레스츠 엘엘씨 | 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법 |
| US11311619B2 (en) * | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
| JP7069032B2 (ja) * | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| WO2021034697A1 (en) * | 2019-08-16 | 2021-02-25 | The Regents Of The University Of California | Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy |
| US12109263B2 (en) * | 2020-09-10 | 2024-10-08 | 7 Hills Pharma LLC | Integrin agonists or activating compounds and methods for making and using same |
| KR20240046893A (ko) * | 2021-08-10 | 2024-04-11 | 텍사스 하트 인스티튜트 | 아미노아릴-인테그린 작용제 화합물 |
| CA3257474A1 (en) * | 2022-05-03 | 2023-11-09 | 7 Hills Pharma Inc. | NEW LIPID-BASED SMALL MOLECULES INTEGRN LIGAND-RECEPTOR AGONIST SUPPORT COMPOSITIONS, PHARMACEUTICAL INTEGRN AGONIST ADJUVANT COMPOSITIONS PREPARED FROM THESE, AND THEIR PROCESSES FOR MANUFACTURE AND USE |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4505227B2 (ja) * | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| AU2005249566B2 (en) * | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| CN101227885A (zh) * | 2005-07-26 | 2008-07-23 | 株式会社资生堂 | 皱纹防止·改善剂 |
| WO2009000406A1 (en) * | 2007-06-22 | 2008-12-31 | Bayer Healthcare Ag | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| CA2760887A1 (en) * | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
| US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| ES2677668T3 (es) * | 2010-11-16 | 2018-08-06 | Texas Heart Institute | Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina |
| AU2015217142B2 (en) | 2014-02-12 | 2020-04-09 | 7 Hills Pharma LLC | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
| CA2954175C (en) | 2014-07-01 | 2023-07-25 | Upendra K. Marathi | Compositions and methods to improve adoptive cell therapies |
| KR20240052078A (ko) * | 2015-04-29 | 2024-04-22 | 7 힐즈 인터레스츠 엘엘씨 | 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법 |
-
2016
- 2016-04-28 KR KR1020247011631A patent/KR20240052078A/ko active Pending
- 2016-04-28 JP JP2017556837A patent/JP2018514562A/ja active Pending
- 2016-04-28 MX MX2017013859A patent/MX2017013859A/es unknown
- 2016-04-28 CA CA2984316A patent/CA2984316A1/en active Pending
- 2016-04-28 WO PCT/US2016/029683 patent/WO2016176400A2/en not_active Ceased
- 2016-04-28 KR KR1020247011632A patent/KR20240052079A/ko active Pending
- 2016-04-28 US US15/140,711 patent/US10342866B2/en active Active
- 2016-04-28 SG SG11201708846XA patent/SG11201708846XA/en unknown
- 2016-04-28 KR KR1020177034574A patent/KR20170136651A/ko not_active Ceased
- 2016-04-28 CN CN201680036891.3A patent/CN107820429B/zh active Active
- 2016-04-28 AU AU2016254034A patent/AU2016254034B2/en active Active
- 2016-04-28 SG SG10201911607YA patent/SG10201911607YA/en unknown
-
2017
- 2017-10-27 IL IL255297A patent/IL255297B/en unknown
- 2017-10-27 MX MX2024002456A patent/MX2024002456A/es unknown
-
2019
- 2019-04-25 US US16/394,270 patent/US10709780B2/en active Active
- 2019-04-25 US US16/394,277 patent/US10716849B2/en active Active
- 2019-07-19 US US16/516,907 patent/US10709781B2/en active Active
-
2021
- 2021-05-06 JP JP2021078488A patent/JP7244570B2/ja active Active
- 2021-06-29 US US17/362,512 patent/US12201686B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016176400A2 (en) | 2016-11-03 |
| US20220001009A1 (en) | 2022-01-06 |
| US12201686B2 (en) | 2025-01-21 |
| US10716849B2 (en) | 2020-07-21 |
| JP2018514562A (ja) | 2018-06-07 |
| WO2016176400A3 (en) | 2016-12-08 |
| KR20170136651A (ko) | 2017-12-11 |
| JP7244570B2 (ja) | 2023-03-22 |
| MX2024002456A (es) | 2024-03-08 |
| KR20240052078A (ko) | 2024-04-22 |
| KR20240052079A (ko) | 2024-04-22 |
| IL255297A0 (en) | 2017-12-31 |
| US10709780B2 (en) | 2020-07-14 |
| AU2016254034A1 (en) | 2017-12-14 |
| US20190343952A1 (en) | 2019-11-14 |
| US10709781B2 (en) | 2020-07-14 |
| CN107820429B (zh) | 2022-08-16 |
| IL255297B (en) | 2021-10-31 |
| AU2016254034B2 (en) | 2021-11-04 |
| JP2021121602A (ja) | 2021-08-26 |
| SG10201911607YA (en) | 2020-01-30 |
| CN107820429A8 (zh) | 2018-06-01 |
| US20160339098A1 (en) | 2016-11-24 |
| US20200054743A1 (en) | 2020-02-20 |
| US20190351052A1 (en) | 2019-11-21 |
| SG11201708846XA (en) | 2017-11-29 |
| CN107820429A (zh) | 2018-03-20 |
| CA2984316A1 (en) | 2016-11-03 |
| US10342866B2 (en) | 2019-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013859A (es) | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. | |
| MX2024002644A (es) | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. | |
| MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| CL2019000326A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
| MX2022012082A (es) | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. | |
| AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| BR112017008710A8 (pt) | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva | |
| MX2015013104A (es) | Composiciones y métodos para la inmunoterapia. | |
| MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
| CL2018002828A1 (es) | Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. | |
| NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| AR105433A1 (es) | Métodos para mejorar la eficacia y expansión de las células inmunes | |
| PE20181075A1 (es) | Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| CR20200460A (es) | Suministro intracelular de biomeléculas para modificar respuestas inmunes | |
| MX389160B (es) | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. | |
| MX2020004094A (es) | Metodos para administrar inmunoterapia con receptores de antigeno quimerico. | |
| MX2015004287A (es) | Composiciones y metodos para inmunoterapia. | |
| HK1255161A1 (zh) | 用於过继性细胞治疗的工程细胞 | |
| MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
| MX2016013747A (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| PE20171135A1 (es) | Metodos para seleccionar una linea de celulas t y donador de la misma para terapia celular adoptiva | |
| MX2021013368A (es) | Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno. |